Friday, February 10, 2012 Last update: 11:33 AM
The Best of U.S. Company Technology News

LA JOLLA--- Stratagene Announces Fourth Quarter 2006 Earnings Release Date and Conference Call

Companies mentioned in this article: Stratagene

Stratagene Corporation (Nasdaq:STGN), today announced that it will release fourth quarter financial results on March 6, 2007 after the market close. The Company will also host a conference call and webcast on March 6, 2007 at 1:30 p.m. Pacific Time to discuss the Company’s fourth quarter and full year results, and current corporate developments. The dial-in number for the conference call is 800-257-2182 for domestic participants and 303-262-2138 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call’s conclusion and will remain available for 7 days. It can be accessed by dialing 800-405-2236 for domestic callers and 303-590-3000 for international callers, using the passcode 11085628#. To access the live webcast of the call, go to Stratagene’s website at www.stratagene.com and click on the Investors icon. An archived webcast will also be available at www.stratagene.com.

About Stratagene Corporation

Stratagene is a developer, manufacturer and marketer of specialized life science research and diagnostic products. The Company's life science research unit supports advances in science by inventing, manufacturing and distributing products that simplify, accelerate and improve research. These products are used throughout the academic, industrial and government research sectors in fields spanning molecular biology, genomics, proteomics, drug discovery and toxicology. The Company's diagnostic unit develops and manufactures products for urinalysis as well as high quality automated instrument and reagent systems that use blood samples to test for more than 1,000 different allergies and autoimmune disorders. In addition, by combining its expertise in diagnostics and molecular biology, as well as its experience with FDA regulatory procedures, the Company is pursuing opportunities to expand its product portfolio to include molecular diagnostic kits and instrumentation. More information is available at www.stratagene.com.